Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer

David E. Gerber, Mark A. Socinski, Joel W. Neal, Heather A. Wakelee, Keisuke Shirai, Lecia V. Sequist, Rachel P. Rosovsky, Rogerio C. Lilenbaum, Bruno R. Bastos, Chao Huang, Melissa L. Johnson, Paul J. Hesketh, Deepa S. Subramaniam, Martin F. Dietrich, Feng Chai, Yunxia Wang, Julia Kazakin, Brian Schwartz, Joan H. Schiller, Julie R. BrahmerRonan J. Kelly

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Fingerprint

Dive into the research topics of 'Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences